SLU-PP-332: The Exercise Mimetic Compound Research Guide

SLU-PP-332: What the Research Shows

SLU-PP-332 is a first-in-class small molecule agonist of estrogen-related receptors (ERRs), developed at Washington University in St. Louis. Unlike traditional exercise mimetics that target single pathways like AMPK, SLU-PP-332 activates all three ERR isoforms — ERR?, ERR?, and ERR? — which are master transcription factors controlling mitochondrial function, oxidative metabolism, and muscle fiber type specification.

Published in Nature in 2023, the discovery of SLU-PP-332 demonstrated that pharmacological activation of ERRs could replicate many of the metabolic benefits of exercise in sedentary animal models, including enhanced endurance, increased fat oxidation, and resistance to diet-induced obesity. Proxiva Labs provides research-grade SLU-PP-332 (Slupp) for qualified investigators, and our research hub covers the latest developments in metabolic peptide and compound science.

Estrogen-Related Receptor Biology

Despite their name, estrogen-related receptors do not bind estrogen and are not part of classical estrogen signaling. ERRs are orphan nuclear receptors that were named for their structural similarity to estrogen receptors. They play critical roles in energy metabolism.

ERR? (Estrogen-Related Receptor Alpha)

ERR? is the most abundant isoform and is highly expressed in metabolically active tissues — heart, skeletal muscle, kidney, and brown adipose tissue. It regulates genes involved in fatty acid oxidation, oxidative phosphorylation, and mitochondrial biogenesis. ERR? works in concert with PGC-1? (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) to drive the transcriptional programs activated by exercise.

ERR? (Estrogen-Related Receptor Beta)

ERR? is less well characterized but plays important roles in early development and stem cell maintenance. In adult tissues, it contributes to metabolic regulation in concert with the other isoforms.

ERR? (Estrogen-Related Receptor Gamma)

ERR? is particularly enriched in oxidative tissues and is a key determinant of muscle fiber type. High ERR? expression promotes the slow-twitch, oxidative fiber phenotype associated with endurance capacity. ERR? drives expression of genes involved in mitochondrial electron transport, fatty acid oxidation, and angiogenesis in skeletal muscle.

Mechanism of Action

SLU-PP-332 acts as a pan-ERR agonist, binding to and activating all three receptor isoforms. This triggers a coordinated transcriptional response that recapitulates key aspects of exercise adaptation (Cho et al., 2023).

Transcriptional Cascade

Upon binding to ERRs, SLU-PP-332 enhances their transcriptional activity on target gene promoters. The downstream effects include:

• Mitochondrial biogenesis — Upregulation of PGC-1?, TFAM, NRF1/NRF2, and mitochondrial DNA replication machinery
• Fatty acid oxidation genes — Increased expression of CPT1b, MCAD, LCAD, and other beta-oxidation enzymes
• Oxidative phosphorylation — Enhanced expression of electron transport chain complexes I-V
• Muscle fiber type genes — Upregulation of slow-twitch myosin heavy chain isoforms (MYH7) and troponin I slow (TNNI1)
• Angiogenic factors — Increased VEGF expression promoting capillary density in muscle

AMPK Crosstalk

While SLU-PP-332 does not directly activate AMPK like MOTS-C, there is significant crosstalk between the ERR and AMPK pathways. AMPK phosphorylates PGC-1?, which then coactivates ERRs, creating a feed-forward loop that amplifies the metabolic response. SLU-PP-332 may potentiate this loop by increasing ERR transcriptional activity.

Exercise Mimetic Properties

The most striking finding from SLU-PP-332 research is its ability to replicate exercise adaptations in sedentary animals.

Endurance Enhancement

In treadmill running tests, mice treated with SLU-PP-332 showed approximately 50% improvement in running endurance compared to vehicle-treated controls — without any exercise training. This remarkable improvement was accompanied by measurable changes in muscle physiology including increased mitochondrial content, improved oxidative capacity, and fiber type shifting toward the slow-twitch, fatigue-resistant phenotype (Cho et al., 2023).

Muscle Fiber Type Switching

One of the most significant findings was SLU-PP-332’s ability to promote conversion of fast-twitch glycolytic fibers (Type IIb) toward slow-twitch oxidative fibers (Type I). This fiber type switching is a hallmark adaptation of endurance training and is directly linked to improved fatigue resistance, enhanced fat utilization, and better metabolic health. Immunohistochemical analysis of treated muscles showed increased proportion of slow myosin heavy chain-positive fibers.

Resistance to Diet-Induced Obesity

Mice receiving SLU-PP-332 while maintained on high-fat diets gained significantly less weight and accumulated less adipose tissue than controls on the same diet. This anti-obesity effect occurred without changes in food intake, suggesting increased energy expenditure rather than appetite suppression as the mechanism.

Fat Oxidation and Metabolic Effects

SLU-PP-332’s effects on fat metabolism extend beyond simple weight management to fundamental changes in how cells process fuel.

Beta-Oxidation Enhancement

Transcriptomic analysis of SLU-PP-332-treated muscle tissue revealed significant upregulation of the entire fatty acid beta-oxidation pathway. Key enzymes including CPT1 (carnitine palmitoyltransferase 1, the rate-limiting enzyme for mitochondrial fatty acid import), MCAD (medium-chain acyl-CoA dehydrogenase), and LCAD (long-chain acyl-CoA dehydrogenase) were all elevated, resulting in a metabolic shift toward preferential fat utilization.

Mitochondrial Biogenesis

SLU-PP-332 significantly increased mitochondrial DNA content and citrate synthase activity in skeletal muscle — two standard markers of mitochondrial mass. Electron microscopy confirmed increased mitochondrial number and improved cristae density in treated muscles, indicating not just more mitochondria but better-quality ones.

Muscle Atrophy Prevention

Beyond performance enhancement, SLU-PP-332 showed protective effects against muscle wasting. In models of disuse atrophy, ERR activation helped maintain muscle mass and function, likely through enhanced protein synthesis signaling and reduced proteolytic pathway activation. This anti-atrophic property has implications for research into sarcopenia, cachexia, and immobilization-related muscle loss.

Comparison with Other Exercise Mimetics

SLU-PP-332’s advantage lies in its activation of a master transcriptional program rather than a single kinase. While AMPK activators like AICAR and MOTS-C produce acute metabolic shifts, ERR activation drives the structural and genomic adaptations that underlie long-term exercise benefits — including muscle remodeling, capillary growth, and mitochondrial biogenesis.

Research Applications

SLU-PP-332 opens several promising research avenues:

• Metabolic syndrome research — investigating whether ERR activation can reverse insulin resistance and dyslipidemia
• Sarcopenia and aging — studying muscle preservation in aging models where exercise capacity is limited
• Cardiovascular research — ERRs are critical for cardiac metabolism, and SLU-PP-332 may have cardioprotective applications
• Neurodegeneration — mitochondrial dysfunction contributes to neurodegenerative diseases, and ERR activation may restore mitochondrial function in neural tissue
• Combination studies — exploring synergistic effects with other metabolic compounds like AOD 9604 or L-Carnitine

Research Protocols in Published Studies

Published research on SLU-PP-332 has utilized the following parameters:

• In vivo dosing: 10-50 mg/kg administered intraperitoneally in mouse models
• Treatment duration: Typically 4-8 weeks for chronic exercise mimetic studies
• In vitro: 1-10 µM in C2C12 myotube cultures and primary muscle cell lines
• Readouts: Treadmill endurance, respiratory exchange ratio, muscle fiber typing (immunohistochemistry), mitochondrial DNA quantification, transcriptomic profiling (RNA-seq)
• Storage: -20°C in powdered form; reconstitute in DMSO for stock solutions

Safety Considerations

As a relatively new compound, SLU-PP-332 has limited safety data compared to more established research peptides. Current observations from published preclinical studies include:

• No reported acute toxicity at standard research doses (10-50 mg/kg) in murine studies
• No observed behavioral abnormalities during chronic treatment protocols
• Body weight changes attributed to metabolic effects rather than toxicity
• Long-term safety, reproductive toxicity, and carcinogenicity data are not yet available

Notably, SLU-PP-332 avoids the safety concerns associated with PPAR? agonists like GW501516, which was abandoned from clinical development due to carcinogenicity in animal models. ERRs regulate a different set of target genes, and the preliminary safety profile appears more favorable, though comprehensive toxicology studies are still needed.

Frequently Asked Questions

Is SLU-PP-332 a peptide?

SLU-PP-332 is technically a small molecule, not a peptide. It is classified as a nuclear receptor agonist. However, it is commonly discussed alongside metabolic peptides like MOTS-C due to its exercise-mimetic properties and similar research applications.

How does SLU-PP-332 compare to MOTS-C?

Both are exercise mimetics but work through different mechanisms. MOTS-C activates AMPK through the folate/purine cycle, producing acute metabolic effects. SLU-PP-332 activates ERR transcription factors, driving structural muscle adaptations including fiber type switching and mitochondrial biogenesis — changes that typically require weeks of exercise training.

Can SLU-PP-332 replace exercise?

Preclinical data suggests SLU-PP-332 can replicate certain metabolic adaptations of exercise (endurance, fat oxidation, fiber type switching), but exercise produces additional benefits (cardiovascular conditioning, bone density, neuroplasticity) that may not be fully captured by ERR activation alone. Research is ongoing.

What is the optimal dose in research studies?

Published murine studies have used 10-50 mg/kg IP. The optimal dose for other model systems has not been established and may vary based on species and research endpoints.

Conclusion

SLU-PP-332 represents a paradigm shift in exercise mimetic research by targeting the ERR transcription factor family — the master regulators of oxidative metabolism and muscle adaptation. Its ability to enhance endurance by ~50%, promote slow-twitch fiber conversion, increase mitochondrial biogenesis, and resist diet-induced obesity in sedentary animals positions it as a powerful research tool for studying metabolic regulation.

As the first compound to pharmacologically activate all three ERR isoforms, SLU-PP-332 opens new avenues for investigating metabolic disease, sarcopenia, and the molecular basis of exercise adaptation. Researchers can explore SLU-PP-332 alongside other metabolic compounds in our research catalog.